Published within
|«
«
|
...
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
Having been expected to become an important treatment option for migraine and compete with the triptan class, the standard of care for the past 20 years, the discontinuation of promising Phase III acute migraine therapy telcagepant will add to Merck's woes. Without telcagepant, the acute migraine market will contract, leaving prophylactic treatment as the biggest opportunity for developers.
Published By Datamonitor
|
01 Aug 2011 |
|
CommentWire
|
Novartis's SMC021 has failed to meet its main fracture reduction endpoint in a Phase III trial for osteoporosis. This is a setback for other firms aiming to stimulate the class's growth, such as Tarsa, which may now struggle to bring its pipeline drug Ostora to the market. Novartis is expected to discontinue the development of SMC021 and focus on more attractive targets for osteoporosis treatment.
Published By Datamonitor
|
16 Nov 2011 |
|
Expert View
|
Targeted therapies have improved treatment outcomes in cancer notably, becoming the leading therapy class in the oncology market. As a result, they are expected to achieve sales of over $42 billion by 2017. Eight more marketed brands are set to achieve blockbuster status over the 10-year forecast period, driven by the persistent unmet need that still exists across a number of tumor types.
Published By Datamonitor
|
03 Oct 2008 |
|
CommentWire
|
Targeted Genetics has begun a second phase I trial of its gene therapy tgAAC94 in patients with inflammatory arthritis. While the product candidate has some way to go yet, as the proprietary technology on which it is based builds on the success of biologic TNF inhibitors in inflammatory disease, if tgAAC94 continues to be successful, it could one day capitalize on a multi-billion dollar market.
Published By Datamonitor
|
13 Oct 2005 |
|
CommentWire
|
Targacept's investigational neuronal nicotinic receptor agonist has failed to meet its primary endpoint in a Phase II trial in adults with attention deficit hyperactivity disorder. Datamonitor expects that future development focus for TC-5619 will shift towards schizophrenia, in view of Phase II data demonstrating efficacy in the treatment of cognitive dysfunction associated with the condition.
Published By Datamonitor
|
25 Mar 2011 |
|
CommentWire
|
On August 8, Genentech [DNA] and OSI Pharmaceuticals [OSIP] announced that the FDA had granted Tarceva orphan drug status for malignant glioma, a very aggressive type of brain tumor. On the same day enrollment for a key phase II trial began. However, it is likely that Tarceva, Genentech's lead pipeline product, will struggle to live up to its hype.<BR />
Published By Datamonitor
|
11 Aug 2003 |
|
CommentWire
|
Encouraged by a partnership that has to date been successful, Millennium has invested further into Seattle Genetics' antibody-drug conjugate technology. As the wait for the first commercially successful antibody-drug conjugate therapeutic continues, pharmaceutical players are actively populating their pipelines with this innovative monoclonal antibody class.
Published By Datamonitor
|
17 Mar 2011 |
|
CommentWire
|
Takeda Pharmaceutical and Abbott Laboratories have announced the imminent conclusion of their joint venture, TAP Pharmaceutical Products. The value of TAP has become questionable in recent years, and the decision to end the partnership is expected to be a positive strategy for both parties. TAP's flagship drugs are to be divided between both companies.
Published By Datamonitor
|
20 Mar 2008 |
|
CommentWire
|
A US court has ruled that the product patent covering Prevacid in the US is valid and enforceable, leaving Teva unable to launch a generic equivalent until May 2009. Although sales of Prevacid are still expected to decrease due to strong market competition, Takeda will look to maintain its market presence by launching a follow-on product.
Published By Datamonitor
|
02 Apr 2008 |
|
CommentWire
|
Following an analysis by independent safety monitors, Synta Pharmaceuticals has been forced to halt a pivotal Phase III trial of elesclomol in advanced melanoma. While this news is particularly disappointing for the melanoma market, where a significant unmet need exists, the setback also presents ominous consequences for Synta.
Published By Datamonitor
|
02 Mar 2009 |
|
|«
«
|
...
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.